Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this exciting learning session on managing Ph negative Acute lymphoblastic leukemia in adults.
Acute Lymphoblastic Leukemia (ALL) is a cancer of the blood and bone marrow that progresses rapidly without treatment. It can reoccur after being in remission from previous treatment. It has been noted that refractory ALL did not respond to treatment indicating the previous treatments did not kill enough leukemia cells (blasts) to reach complete remission.
Ph-positive ALL is a special type of ALL in which a genetic mutation is observed in the Philadelphia chromosome. In the case of Ph-negative ALL, genetic disparities are also observed and most importantly in Ph neg ALL there is a disproportionate survival rate among the patients.
Managing Ph neg ALL often becomes difficult, however, the procedures of management of Philadelphia chromosome (Ph)–negative acute lymphoblastic leukemia (ALL) have changed dramatically in recent years leading to a positive vibe for the situation.
Therefore, have overall knowledge regarding the management of Ph negative ALL. Listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Testosterone recovery linked to overall survival in high-risk prostate cancer
2.
Knowing about and avoiding bladder cancer.
3.
AI model combines clinical and magnetic resonance data to improve prediction of breast cancer recurrence
4.
How 7,000 steps a day could help reduce your risk of cancer
5.
ACS Guidelines Expand Lung Cancer Screening Eligibility -- Is That a Good Thing?
1.
Cancer Stem Cells: The Seeds of Tumorigenesis and Recurrence
2.
Clinical Analysis of Prostate Cancer
3.
Revolutionizing Cancer Care: The Impact of Darzalex Faspro
4.
Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review
5.
Exploring the Pleomorphic Adenoma: A Unique and Varied Tumor
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
2.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
3.
Navigating the Complexities of Ph Negative ALL - Part XII
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part III
5.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- The Conclusion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation